EQRx 過去の業績
過去 基準チェック /06
EQRx's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 17.4% annually.
主要情報
-12.3%
収益成長率
98.2%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | n/a |
| 株主資本利益率 | -22.2% |
| ネット・マージン | n/a |
| 前回の決算情報 | 30 Sep 2023 |
最近の業績更新
更新なし
Recent updates
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely
Jul 25
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Feb 22We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate
Nov 08EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs
Aug 28 EQRx GAAP EPS of -$0.17 beats by $0.03
Aug 11Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation
Jul 24We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth
Apr 08EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Dec 24収支内訳
収支内訳
EQRx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -260 | 104 | 204 |
| 30 Jun 23 | 0 | -263 | 114 | 240 |
| 31 Mar 23 | 0 | -272 | 124 | 244 |
| 31 Dec 22 | 0 | -169 | 129 | 227 |
| 30 Sep 22 | 0 | -146 | 138 | 211 |
| 30 Jun 22 | 0 | -100 | 121 | 179 |
| 31 Mar 22 | 0 | -53 | 102 | 153 |
| 31 Dec 21 | 0 | -100 | 80 | 116 |
| 30 Sep 21 | 0 | -279 | 50 | 229 |
| 30 Jun 21 | 0 | -296 | 40 | 256 |
| 31 Mar 21 | 0 | -269 | 32 | 237 |
| 31 Dec 20 | 0 | -250 | 27 | 223 |
質の高い収益: EQRX is currently unprofitable.
利益率の向上: EQRX is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: EQRX is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
成長の加速: Unable to compare EQRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: EQRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
株主資本利益率
高いROE: EQRX has a negative Return on Equity (-22.23%), as it is currently unprofitable.